[Lymphoblastic non-Hodgkin's lymphoma: estimation of the survival of patients with the disseminated form of the disease (stages III and IV) treated by the LSA2-L2 protocol].
We analyze the survival rate in 17 pediatric patients (twelve males and five females) that were diagnoses of non-Hodgkin's lymphoblastic lymphoma (cases with Burkitt's lymphoma were excluded) during the period from 1982 to 1990. All of them were treated using the LSA2-L2 therapeutic protocol. The follow-up period ranged from 14 to 99 months (follow-up median 43 months). Staging of our newly diagnosed patients, we found 9 patients in stage III and 8 in stage IV disease. Survival was analyzed by the Kaplan-Meier method. The overall survival rate of our patients is 69.5% and the disease free survival is 62.6%. The disease free survival for separated stages is 66.5% for stage III and 58.3% for stage IV. We compare our results with other casuisties published in literature.
Pisón Garcés
J
J
Unidad de Oncopediatría, Hospital Infantil Miguel Servet, Zaragoza.
Buñuel Alvarez
J C
JC
Domínguez Fenollé
M P
MP
Castillo Laita
J A
JA
Cenarro Guerrero
T
T
Monreal Gálvez
M J
MJ
Arana Navarro
T
T
Hernández Gayá
A
A
D002648:Child; D002985:Clinical Protocols; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D013030:Spain / Q000453:epidemiology; D015996:Survival Rate
Linfoma no Hodgkin de tipo linfoblástico: evaluación de la supervivencia en pacientes con enfermedad diseminada (estadío III y IV) tratados con el protocolo LSA2-L2.